Skip to main content
Journal of Dermatological Case Reports logoLink to Journal of Dermatological Case Reports
. 2013 Dec 30;7(4):113–120. doi: 10.3315/jdcr.2013.1157

Wells syndrome (eosinophilic cellulitis): Proposed diagnostic criteria and a literature review of the drug-induced variant

Kara Heelan 1,3,*, John F Ryan 2, Neil H Shear 3, Conleth A Egan 1
PMCID: PMC3888780  PMID: 24421864

Abstract

Background

Wells syndrome is an uncommon inflammatory dermatosis first described in 1971 by Wells. The clinical eruption is characterized by varying morphology and severity and usually follows a relapsing remitting course. The majority of the reported cases are of unknown etiology, drug induced Wells syndrome has rarely been reported. A literature search using MEDLINE was performed. We recorded the features of our case and of the additional cases of drug induced Wells syndrome in the literature.

Main observations

Including our case there are 25 cases of drug-induced Wells syndrome reported. Causative drugs include antibiotics, anticholinergic agents, anaesthetics, non-steroidal anti-inflammatory agents, thyroid medications, chemotherapeutic agents, thiomersal containing vaccinations, anti-tumor necrosis factor agents and thiazide diuretics.

Conclusions

To the authors knowledge this is the first reported case of drug-induced Wells syndrome from thiazide diuretics. The diagnosis of Wells syndrome is often controversial and we propose a set of diagnostic criteria.

Keywords: antibiotics, aliskiren, drug-induced, drug reaction, diuretic, eosinophilia, etanercept, hydrochlorothiazide, hypertension, penicillin

Introduction

Wells syndrome (WS) is an uncommon inflammatory dermatosis first described in 1971 by Wells.[1] The clinical eruption commences with a prodromal burning or pruritic sensation, followed by urticarial or infiltrative erythema which spreads centrifugally and clears centrally. It is characterized by varying severity and usually follows a relapsing remitting course. The etiology is unknown, however drugs have been associated with onset of this disorder. We recorded the features of our case and of the additional cases of drug induced WS in the literature.

Case Report

We report a 61-year-old male with a longstanding history of biopsy proven eczema. A new extensive eruption with erythematous swollen plaques on the forearms and back developed [Fig. 1 and [2]. Blood tests demonstrated raised eosinophils 12%, 1.00 (0.04-0.4), IgE 65 (2-100 U/ml), normal ESR, renal and liver function. ANA and ENA were negative. Creatinine kinase (CK) was persistently raised (436 U/L), aldolase was normal. Systemic examination revealed no lymphadenopathy, organomegaly or proximal muscle weakness. A CT-thorax, abdomen and pelvis was normal. Metachronous biopsies were performed, the first showed a mild spongiotic dermatitis, the second revealed a spongiotic epidermis, dermal eosinophils and flame figures [Fig. 3]. WS was considered as a diagnosis. Treatment was instituted with topical betamethasone valerate. However, as the rash continued to relapse and remit oral steroids were commenced. Treatment yielded only temporary improvement with a flare on discontinuation of oral steroids. Medical history included hypertension, medications were tamsulosin, lercandipine and a combination drug (Rasilez®) of a direct rennin inhibitor (aliskiren) and hydrochlorothiazide diuretic. Lymphocyte transformation testing (LTT) to all medications was performed. Results revealed a stimulation index (SI) 3.5 to hydrochlorothiazide indicating type IV sensitization. All other drugs tested demonstrated SI < 1, (normal = SI < 2). Rasilez® was discontinued and the rash resolved. CK levels normalized after discontinuation of the drug. Followup histopathology 3 months later revealed background changes of eczema and no evidence of flame figures.

Figure 1.

Figure 1

Erythematous swollen plaques on right forearm.

Figure 2.

Figure 2

Erythematous lesions on the back.

Figure 3.

Figure 3

Hematoxylin and eosin (400 x) stain showing flame figures.

Discussion

Wells in 1971 first described "granulomatous dermatitis with eosinophilia",[1] it was later named eosinophilic cellulitis and over the years became known as WS.[2] Typical rashes cross a varied spectrum from a sudden eruption of cellulitic lesions, sometimes associated with blistering to a more milder form with annular or circinate erythematous plaques with infiltrated borders persisting or recurring over months to years,[3] spontaneous resolution being the rule. The stages of histopathological changes described include an early phase exhibiting dermal oedema, and diffuse dermal infiltration of eosinophils, a subacute phase with a characteristic infiltrate of phagocytic histiocytes together with flame figures where amorphous or granular eosinophilic material adheres to collagen and an older phase showing fewer eosinophils, histiocytes, giant cells between collagen bundles along with remaining flame figures.[4]

Flame figures are not pathognomic and may be detected in other inflammatory dermatoses and also in dermatoses associated with eosinophilia e.g. pemphigoid and its variants, severe prurigo, eczema and follicular mucinoses. In a case series by Caputo et al.,[5] approximately 50% of patients showed evidence of flame figures. Treatment is generally with low dose oral steroids, which is not always effective and management with other agents including griseofulvin, dapsone, antihistamines and sulphones have been endeavoured with varying success.[6]

The differential diagnosis of WS is broad and includes infections, such as bacterial cellulitis, Toxocara canis, erythema chronicum migrans, arthropod bites and hypereosinophilc syndrome, chronic idiopathic urticaria and Churg-Strauss syndrome.[6] The etiology remains unknown, but reported triggering factors have been reported including infection, arthropod bites, haematological disorders and drugs.[6] The role of a hypersensitivity reaction has been suggested due to the common association between atopic disorders, drug precipitation of the disorder and the frequent occurrence of peripheral eosinophilia.[4]

A Medline search was performed and we recorded the features both in our case and of the twenty-four additional cases of drug-induced WS in the English literature [Table 1]. Drugs which have been reported to have a causal relationship with WS include antibiotics,[1-3,7-12] anticholinergic agents,[2] anaesthetics,[2,7,9] non-steroidal anti-inflammatory agents,[2,9,12] thyroid medications,[2,11] chemotherapeutic agents,[8,13] thiomersal containing vaccinations[14-16] and anti-TNF agents.[17-19] Of the twenty-five reported cases eighteen were female and the ages of onset ranged from 3.5 years to 85 years old. Peripheral eosinophilia was reported in 17 cases, this was normal in 4 cases and not reported in 4 other cases. Increased IgE was described in 4 cases. Morphology and sites of the described associated rashes exhibited many variations. In 2 cases flame figures were not seen. A further case while not deemed to be induced by drugs was associated with Danazol induced exacerbations of flare ups.[20]

Table 1. Summary of literature review of cases of drug-induced Wells Syndrome.

Case Sex Age Morphology Sites Pathology Potential Implicated Drug/s Peripheral Eosinophilia IgE Authors
1 F 28 Generalized plaques with greenish oedema
Erythematous borders
Drying central blisters
Lower limbs
Trunk
Dermal infiltration with eosinophils
Many flame figures
Ampicillin 2300/mm3   Wells
et al.3
2 M 12 Infiltrated pruritic lesions widespread Trunk
Thighs
Dermal oedema, eosinophils and phagocytic histiocytes
Flame figures
Penicillin 44%   Wells
et al.3
3 M 11 Urticarial lesions and turgid erythematous plaques. Some blisters Widespread
1/3 of body
Dermal oedema, eosinophils and phagocytic histiocytes
Flame figures
Penicillin     Wells
et al.3
4 F 56 Tender plaques of “cellulitis” Trunk
Extremities
Dermal infiltrate of eosinophils and histiocytes
Flame figures
Focal microgranulomas
Anticholinergics
Antibiotics
Anaesthetics
19.5%   Spiegel
et al.2
5 F 66 Cellulitic, erythematous lesions and erythematous infiltrative lesions Right arm
Trunk
Extremities
Diffuse eosinophilc infiltrate of upper dermis with oedema formation
Flame figures
Probable penicillin
Other possibilities:
(Thyroglobulin, Aspirin Chlorodiazepoxide, diazepam, Clidinium bromide, estrogen, Acetaminophen)
34%   Spiegel
et al.2
6 F 26 Recurrent papulovesicular eruption with associated oedema and erythema Limbs
Back
Forehead
Dermal eosinophilia
Flame figures
Histiocytes palisading around areas of altered collagen
Erythromycin 548/mm3   Peters
et al.7
7 F 56 Pruritic and painful urticarial plaques Trunk, thighs, neck, axillae, forehead Dermal eosinophilia
Flame figures
Histiocytes palisading around areas of altered collagen
Xylocaine, Carbocaine
Valium, Penicillin
1406/mm3   Peters
et al.7
8 M 26 Scattered target and urticarial lesions
Papules and follicular pustules
Trunk
Face
Eosinophilia
Flame figures (on third biopsy)
Tetracycline 6% Slightly elevated Brehmer-
Andersson
et al.8
9 F 42 Papulovesicular, urticarial infiltrations
Oedema
Trunk, limbs
Periorbital
Dermal eosinophilia
Flame figures
Bleomycin 6%   Brehmer-
Andersson
et al.8
10 F 56 Erythematous, oedematous lesions Face
trunk, extremities
Dermal eosinophilia
Flame figures
Chlorambucil 10.0 - 11.5%   Brehmer-
Andersson
et al.8
11 F 42 Itchy erythematous, infiltrated plaques with greenish centres and erythematous borders
Some bullous lesions
Limbs, trunk, face Dense inflammatory infiltrate eosinophils and macrophages
Flame figures
Oedema
Lincomycin, Thiopental, Acetyl salicyclic acid, pholcodin 1460/mm3 570 μg/L
(n=<35
0 μg/L)
Ferrier et al.9
12 M 60 Pruritic, erythematous papules and vesicles Trunk
Extremities
Dermal infiltrate eosinophils & neutrophils
Flame figures
Minocycline 6%, 1490/μL 2327 U/ml
(n=up to 260 U/ml)
Andreano
et al.10
13 F 69 Erythematous indurated pruritic plaques Buttocks
Left groin
Dermal and subcutaneous Eosinophils and lymphocytes. Histiocytes and clusters of eosinophilic granules on collagen fibers
No flame figures
Tetanus vaccination Normal   Moreno
et al.16
14 M 85 Erythematous, oedematous plaques Left posterior arm and hand Superficial and mid-dermal perivascular and interstitial pattern of inflammation
Eosinophils
Flame figures
Clindamycin     Moossavi
et al.11
15 F 57 Erythematous, indurated plaques Posterior neck, trunk, extremities Dermal eosinophils
Flame figures
Thyroxine 15%   Moossavi
et al.11
16 F 28 Erythematous, papular lesions
Bullous lesions
Vesiculop apules
Erythematous plaque
Dorsal feet
Right wrist
Fingers
Left foot, right ankle
Eosinophilic infiltrate dermis and subcutaneous tissue
Flame figures
Tenoxicam and diclofenac sodium and/or amoxicillin 16.5%   Seckin
et al.12
17 M 3.5 Episode 1. Rapid onset erythema, ulceration and swelling. Blisters
Episode 2. Vesicular annular plaques with yellowish centre and erythematous border
Episode 3. Similar Inflammatory lesions
Left foot
Right heel
Upper and lower limbs
Episode 1. Prominent dermal infiltrate of eosinophils. Prominent flame figures
Episode 2. Dermal infiltrate, eosinophils and flame figures
Thiomersal containing vaccinations
(Episode 1 and 2: Hepatitis B vaccination,
Episode 3: Triple Antigen vaccine)
Episode 1. 0.62 X109/L
Episode 2. 0.57 X109/L (n=0.04-0.40)
  Koh
et al.15
18 F 67 Ulcerated papules and plaques Trunk Eosinophilia Perivascular & interstitial infiltrate
Flame figures
2-Chlorodeoxyadenosine Normal   Rossini
et al.13
19 F 59 Papules and crusts Face and legs Eosinophilia
Perivascular dermatitits
Flame figures
2-Chlorodeoxyadenosine Normal   Rossini
et al.13
20 F 62 Erythematous, ulcerated vesicular, pruritic lesions Generalized Epidermal necrosis, panniculitis, dermal oedema
Flame figures
2-Chlorodeoxyadenosine Normal   Rossini
et al.13
21 F 57 Erythematous plaques at injection site Right thigh Dermal oedema and eosinophilic infiltrate
Flame figures
Etanercept     Winfield
et al.18
22 F 72 Urticarial plaques at injection site Left thigh Dermal eosinophilic infiltrate
Flame figures
Adalimumab     Boura
et al.19
23 F 7 Erythematous, vesicular oedematous, plaques Feet, upper limbs Dermal eosinophilic infiltrates
Flame figures
Tetanusdiphtheria vaccine 16%
976/mm3
  Calvert
et al.14
24 F 68 Extensive skincoloured papules with erythematous rim Back and abdomen Dense lymphocytic infiltrate, eosinophils Infliximab 5.3%,
0.67x109
  Tugnet
et al.17
25 M 61 Erythematous oedematous plaques Forearms
Back
Dermal eosinophils and flame figures Hydrochlorothiazide 12%, 1.00 x 109 IgE 65 (2-100 U/ml) Current case

Thiazide diuretics or aliskiren have not previously been reported to be associated with WS. LTT has been used for over 30 years as part of the diagnosis of possible drug allergies. A population of the patients’ peripheral blood lymphocytes is co-cultured, together with non-toxic concentrations of the suspected drug. An enhanced proliferative response in the presence of the suspected drug is interpreted as a sign of a drug-specific T cell sensitization. Proliferative responses are calculated as SI. SI > 2 is the cut-off widely utilized to indicate a positive test.[21] The potential of the thiazide group of drugs to cause cutaneous reactions is well recognized.[22] Rasilez® has been associated with increased CK levels.[23] The diagnosis ofWS has been controversial over the years. Whether eosinophilic cellulitis constitutes a disease entity or merely represents a hypersensitivity reaction to different stimuli is still debated.[11]

El-Khalawany et al. presented the long-term follow-up of 10 patients with the annular variant of WS.[24] Seven patients had associated systemic disease. Recently Sinnoi et al. published a literature review of all reported cases of idiopathic WS.[25] Thirty-two patients were described and an algorithm to decipher it from infectious cellulitis was illustrated. We examined the diagnostic criteria of potential differential diagnosis including; Hypereosinophilic syndrome, Churg-Strauss syndrome and Chronic idiopathic urticaria. Based on these and using the available level 4 evidence we have proposed a set of diagnostic criteria for WS in an aim to improve diagnostic accuracy. The sensitivity and specificity are attributed to the cases which we have reviewed. We included four major (two of which need to be present) and four minor criteria (at least one of which needs to be present). These are pertaining to factors which exclude other potential diagnosis particularly from our proposed most common differentials [Table 2].

Table 2. Criteria for Hypereosinophilic Syndrome, Churg-Strauss Syndrome, Chronic idiopathic urticaria, Proposed diagnostic criteria for Wells syndrome.

Chusid criteria for hypereosinophilic syndrome26 ACR criteria for Churg-Strauss syndrome27 Chronic idiopathic urticaria28 Proposed diagnostic criteria for Wells syndrome
A sustained absolute eosinophil count (AEC) greater than >1500/μl is present, which persists for longer than 6 months

No identifiable etiology for eosinophilia present

Patients must have signs and symptoms of organ involvement
Asthma (wheezing, expiratory rhonchi)

Eosinophilia of more than 10% in peripheral blood

Paranasal sinusitis

Pulmonary infiltrates (may be transient)

Histological proof of vasculitis with extravascular eosinophils

Mononeuritis multiplex or polyneuropathy
Spontaneous wheals and/or angioedema > 6 weeks

Differential blood count and ESR or CRP omission of suspected drugs (e.g. NSAID)

Test for:
- infectious diseases (e.g. Helicobacter pylori);
- type I allergy;
- functional autoantibodies;
- thyroid hormones and autoantibodies;
- skin tests including physical tests;
- pseudoallergen-free diet for 3 weeks and tryptase;
- autologous serum skin test, lesional skin biopsy
Major (2 of 4 required)

Diverse clinical picture to include any of the previously reported variants5
- Plaque-type
- Annular-granuloma-like
- Urticaria-like
- Papulovesicular
- Bullous
- Papulonodular
- Fixed-Drug Eruption-like


Relapsing, remitting course

No evidence systemic disease

Histology: eosinophilic infiltrates, no vasculitis


Minor (at least 1 required)

Flame figures

Histology: Granulomatous change

Peripheral eosinophila not persistent and not greater than >1500/μl

Triggering factor (e.g. drug)

Conclusion

The combination of a typical history, a striking clinical picture, characteristic histologic findings and elimination of other possible causes by a thorough history and laboratory examination ostensibly permits a diagnosis of WS.[6] We propose that this is a case of WS developing after treatment with thiazide diuretic in a patient with a history of eczema. This is substantiated by our patient showing the classic histopathologic findings of eosinophilic cellulitis, his skin lesions being typical of a milder subtype which varied in duration of persistence, disappearing while on oral steroids and resolving on discontinuation of thiazide. Hypersensitivity to thiazide was confirmed by LTT and repeat histology after resolution of the Wells rash revealed chronic eczematous changes. We suggest that WS with typical clinical and histopathologic findings may be a side effect of the thiazide subgroup of diuretics.

References

  1. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc. 1971;57:46–56. [PubMed] [Google Scholar]
  2. Spigel GT, Winkelmann RK. Wells' syndrome. Recurrent granulomatous dermatitis with eosinophilia. Arch Dermatol. 1979;115:611–613. doi: 10.1001/archderm.115.5.611. [DOI] [PubMed] [Google Scholar]
  3. Wells GC, Smith NP. Eosinophilic cellulitis. Br J Dermatol. 1979;100:101–109. doi: 10.1111/j.1365-2133.1979.tb03574.x. [DOI] [PubMed] [Google Scholar]
  4. Mitchell AJ, Anderson TF, Headington JT, Rasmussen JE. Recurrent granulomatous dermatitis with eosinophilia. Wells' syndrome. Int J Dermatol. 1984;23:198–202. doi: 10.1111/j.1365-4362.1984.tb04511.x. [DOI] [PubMed] [Google Scholar]
  5. Caputo R, Marzano AV, Vezzoli P, Lunardon L. Wells syndrome in adults and children: a report of 19 cases. Arch Dermatol. 2006;142:1157–1161. doi: 10.1001/archderm.142.9.1157. [DOI] [PubMed] [Google Scholar]
  6. Aberer W, Konrad K, Wolff K. Wells' syndrome is a distinctive disease entity and not a histologic diagnosis. J Am Acad Dermatol. 1988;18:105–114. doi: 10.1016/s0190-9622(88)70016-x. [DOI] [PubMed] [Google Scholar]
  7. Peters MS, Schroeter AL, Gleich GJ. Immunofluorescence identification of eosinophil granule major basic protein in the flame figures of Wells' syndrome. Br J Dermatol. 1983;109:141–148. doi: 10.1111/j.1365-2133.1983.tb07074.x. [DOI] [PubMed] [Google Scholar]
  8. Brehmer-Andersson E, Kaaman T, Skog E, Frithz A. The histopathogenesis of the flame figure in Wells' syndrome based on five cases. Acta Derm Venereol. 1986;66:213–219. [PubMed] [Google Scholar]
  9. Ferrier MC, Janin-Mercier A, Souteyrand P, Bourges M, Hermier C. Eosinophilic cellulitis (Wells' syndrome): ultrastructural study of a case with circulating immune complexes. Dermatologica. 1988;176:299–304. doi: 10.1159/000248740. [DOI] [PubMed] [Google Scholar]
  10. Andreano JM, Kantor GR, Bergfeld WF, Tuthill RJ, Taylor JS. Eosinophilic cellulitis and eosinophilic pustular folliculitis. J Am Acad Dermatol. 1989;20:934–936. doi: 10.1016/s0190-9622(89)70113-4. [DOI] [PubMed] [Google Scholar]
  11. Moossavi M, Mehregan DR. Wells' syndrome: a clinical and histopathologic review of seven cases. Int J Dermatol. 2003;42:62–67. doi: 10.1046/j.1365-4362.2003.01705.x. [DOI] [PubMed] [Google Scholar]
  12. Seckin D, Demirhan B. Drugs and Wells' syndrome: a possible causal relationship? Int J Dermatol. 2001;40:138–140. [PubMed] [Google Scholar]
  13. Rossini MS, de Souza EM, Cintra ML, Pagnano KB, Chiari AC, Lorand-Metze I. Cutaneous adverse reaction to 2-chlorodeoxyadenosine with histological flame figures in patients with chronic lymphocytic leukaemia. J Eur Acad Dermatol Venereol. 2004;18:538–542. doi: 10.1111/j.1468-3083.2004.00969.x. [DOI] [PubMed] [Google Scholar]
  14. Calvert J, Shors AR, Hornung RL, Poorsattar SP, Sidbury R. Relapse of Wells' syndrome in a child after tetanus-diphtheria immunization. J Am Acad Dermatol. 2006;54:S232–233. doi: 10.1016/j.jaad.2005.10.035. [DOI] [PubMed] [Google Scholar]
  15. Koh KJ, Warren L, Moore L, James C, Thompson GN. Wells' syndrome following thiomersal-containing vaccinations. Australas J Dermatol. 2003;44:199–202. doi: 10.1046/j.1440-0960.2003.00678.x. [DOI] [PubMed] [Google Scholar]
  16. Moreno M, Luelmo J, Monteagudo M, Bella R, Casanovas A. Wells' syndrome related to tetanus vaccine. Int J Dermatol. 1997;36:524–525. doi: 10.1111/j.1365-4362.1997.tb01153.x. [DOI] [PubMed] [Google Scholar]
  17. Tugnet N, Youssef A, Whallett AJ. Wells' syndrome (eosinophilic cellulitis) secondary to infliximab. Rheumatology (Oxford) 2012;51:195–196. doi: 10.1093/rheumatology/ker322. [DOI] [PubMed] [Google Scholar]
  18. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142:218–220. doi: 10.1001/archderm.142.2.218. [DOI] [PubMed] [Google Scholar]
  19. Boura P, Sarantopoulos A, Lefaki I, Skendros P, Papadopoulos P. Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab. Ann Rheum Dis. 2006;65:839–840. doi: 10.1136/ard.2005.044685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Coldiron BM, Robinson JK. Low-dose alternate-day prednisone for persistent Wells' syndrome. Arch Dermatol. 1989;125:1625–1626. [PubMed] [Google Scholar]
  21. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997;27:175–181. [PubMed] [Google Scholar]
  22. Baer RL, Harris H. Types of cutaneous reactions to drugs. Importance in recognition of adverse reactions. JAMA. 1967;202:710–713. [PubMed] [Google Scholar]
  23. Novartis Pharmaceuticals. RASILEZ HCT aliskiren (as aliskiren fumarate) & hydrochlorothiazide tablets. In: Product Monograph. Canada: Novarits Pharmaceuticals; 2009. p. 15. [Google Scholar]
  24. El-Khalawany M, Al-Mutairi N, Sultan M, Shaaban D. Eosinophilic annular erythema is a peculiar subtype in the spectrum of Wells syndrome: a multicentre long-term follow-up study. J Eur Acad Dermatol Venereol. 2013;27:973–979. doi: 10.1111/j.1468-3083.2012.04616.x. [DOI] [PubMed] [Google Scholar]
  25. Sinno H, Lacroix JP, Lee J, Izadpanah A, Borsuk R, Watters K, Gilardino M. Diagnosis and management of eosinophilic cellulitis (Wells' syndrome): A case series and literature review. Can J Plast Surg. 2012;20:91–97. doi: 10.1177/229255031202000204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1–27. [PubMed] [Google Scholar]
  27. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY. et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis) Arthritis Rheum. 1990;33:1094–1100. doi: 10.1002/art.1780330806. [DOI] [PubMed] [Google Scholar]
  28. Zuberbier T, Asero R, Bindslev-Jensen C. et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417–1426. doi: 10.1111/j.1398-9995.2009.02179.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Dermatological Case Reports are provided here courtesy of Spejaliści Dermatolodzy

RESOURCES